

Gemma Gatta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9173359/publications.pdf>

Version: 2024-02-01

225
papers

27,139
citations

8755

77
h-index

7234

158
g-index

231
all docs

231
docs citations

231
times ranked

33390
citing authors

#	ARTICLE	IF	CITATIONS
1	A system for classifying cancers diagnosed in adolescents and young adults. <i>Cancer</i> , 2020, 126, 4634-4659.	2.0	25
2	Is the cancer survival improvement in European and American adolescent and young adults still lagging behind that in children?. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27407.	0.8	32
3	Rare cancers: A network for better care. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1-2.	0.5	9
4	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2019, 20, e652-e660.	1.1	6
5	Changes in life expectancy for cancer patients over time since diagnosis. <i>Journal of Advanced Research</i> , 2019, 20, 153-159.	4.4	16
6	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. <i>Frontiers in Oncology</i> , 2019, 9, 837.	1.3	13
7	Incidence of rare cancers in the city of São Paulo, Brazil. <i>Tumori</i> , 2019, 105, 22-30.	0.6	6
8	Prognosis and cure of long-term cancer survivors: A population-based estimation. <i>Cancer Medicine</i> , 2019, 8, 4497-4507.	1.3	24
9	The European study on centralisation of childhood cancer treatment. <i>European Journal of Cancer</i> , 2019, 115, 120-127.	1.3	12
10	Rare cancers in childhood and adolescence in Brazil: First report of data from 19 population-based cancer registries. <i>Cancer</i> , 2019, 125, 2638-2646.	2.0	10
11	Excess risk of dying of other causes of cured cancer patients. <i>Tumori</i> , 2019, 105, 199-204.	0.6	4
12	Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. <i>European Journal of Cancer</i> , 2019, 110, 120-126.	1.3	61
13	Integrating population data in a computerized Decision Support System for Head and Neck Cancer. , 2019, , .		0
14	Treatment challenges in and outside a network setting: Soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 31-39.	0.5	27
15	Epidemiology of rare cancers and inequalities in oncologic outcomes. <i>European Journal of Surgical Oncology</i> , 2019, 45, 3-11.	0.5	47
16	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019, 45, 46-51.	0.5	3
17	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 75-80.	0.5	15
18	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. <i>European Journal of Surgical Oncology</i> , 2019, 45, 60-66.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Treatment challenges in and outside a network setting: Head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2019, 45, 40-45.	0.5	27
20	Bayesian estimates of the incidence of rare cancers in Europe. <i>Cancer Epidemiology</i> , 2018, 54, 95-100.	0.8	11
21	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37.5 million patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <i>Lancet</i> , 2018, 391, 1023-1075.	6.3	3,228
22	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
23	Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study. <i>Cancer Epidemiology</i> , 2018, 56, 146-153.	0.8	30
24	An estimate of the number of people in Italy living after a childhood cancer. <i>International Journal of Cancer</i> , 2017, 140, 2444-2450.	2.3	20
25	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 136-152.	2.0	125
26	Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89,828 children from 198 registries in 53 countries. <i>Lancet Haematology</i> , 2017, 4, e202-e217.	2.2	141
27	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. <i>European Journal of Cancer</i> , 2017, 77, 140-152.	1.3	72
28	Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S24-S31.	0.6	20
29	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S100-S106.	0.6	0
30	Trends in net survival lung cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S70-S76.	0.6	9
31	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. <i>European Journal of Cancer Prevention</i> , 2017, 26, S9-S15.	0.6	7
32	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S114-S120.	0.6	4
33	Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S48-S55.	0.6	14
34	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S56-S62.	0.6	3
35	Primary central nervous system lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 97-110.	2.0	79
36	Central nervous system gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 213-234.	2.0	109

#	ARTICLE	IF	CITATIONS
37	Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). <i>Gynecologic Oncology</i> , 2017, 144, 396-404.	0.6	93
38	The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). <i>Gynecologic Oncology</i> , 2017, 144, 405-413.	0.6	93
39	Cholangiocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 11-31.	2.0	96
40	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: AÂEUROCARE-5 study. <i>European Journal of Cancer</i> , 2017, 84, 335-353.	1.3	29
41	Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S85-S91.	0.6	9
42	Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S121-S127.	0.6	3
43	Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S77-S84.	0.6	13
44	Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S92-S99.	0.6	5
45	Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S40-S47.	0.6	7
46	Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S16-S23.	0.6	7
47	Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S32-S39.	0.6	4
48	Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S63-S69.	0.6	15
49	Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S107-S113.	0.6	10
50	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnetâ€”a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 1022-1039.	5.1	285
51	Geographical variability in survival of European children with central nervous system tumours. <i>European Journal of Cancer</i> , 2017, 82, 137-148.	1.3	33
52	Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material. <i>European Journal of Cancer Prevention</i> , 2017, 26, S3-S8.	0.6	3
53	Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26348.	0.8	32
54	Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. <i>Tumori</i> , 2017, 103, 292-298.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Childhood cancer and environmental integrity: a commentary and a proposal. <i>Revista De Saude Publica</i> , 2017, 51, 29.	0.7	2
56	Childhood medulloblastoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 35-51.	2.0	119
57	Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. <i>Lancet Oncology</i> , The, 2016, 17, e163-e172.	5.1	56
58	Survival of European adolescents and young adults diagnosed with cancer in 2000â€“07: population-based data from EUROCORE-5. <i>Lancet Oncology</i> , The, 2016, 17, 896-906.	5.1	205
59	Neuroblastoma (Peripheral neuroblastic tumours). <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 163-181.	2.0	101
60	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. <i>European Journal of Cancer</i> , 2016, 67, 91-98.	1.3	17
61	Thymoma and thymic carcinomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 332-350.	2.0	220
62	Estimates of prostate cancer burden in Italy. <i>Cancer Epidemiology</i> , 2016, 40, 166-172.	0.8	10
63	Paranasal sinus cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 45-61.	2.0	41
64	Survival of male genital cancers (prostate, testis and penis) in Europe 1999â€“2007: Results from the EUROCORE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2206-2216.	1.3	82
65	Age and case mix-standardised survival for all cancer patients in Europe 1999â€“2007: Results of EUROCORE-5, a population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2120-2129.	1.3	66
66	Specialized teams or specialist networks for rare cancers?. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1115-1117.	0.5	10
67	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015, 26, 300-306.	0.6	77
68	Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data. <i>Annals of Oncology</i> , 2015, 26, 1263-1268.	0.6	65
69	Urinary tract cancer survival in Europe 1999â€“2007: Results of the population-based study EUROCORE-5. <i>European Journal of Cancer</i> , 2015, 51, 2217-2230.	1.3	75
70	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCORE-5 population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2130-2143.	1.3	344
71	Survival for oesophageal, stomach and small intestine cancers in Europe 1999â€“2007: Results from EUROCORE-5. <i>European Journal of Cancer</i> , 2015, 51, 2144-2157.	1.3	138
72	Cancer survival in Europe, 1999â€“2007: Doing better, feeling worse?. <i>European Journal of Cancer</i> , 2015, 51, 2101-2103.	1.3	8

#	ARTICLE	IF	CITATIONS
73	The EUROCORE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. <i>European Journal of Cancer</i> , 2015, 51, 2104-2119.	1.3	97
74	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCORE-5. <i>European Journal of Cancer</i> , 2015, 51, 2169-2178.	1.3	115
75	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015, 26, 838-847.	0.6	21
76	Global surveillance of cancer survival 1995-2009: analysis of individual data for 25-676-887 patients from 279 population-based registries in 67 countries (CONCORD-2). <i>Lancet</i> , The, 2015, 385, 977-1010.	6.3	1,863
77	Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. <i>Cancer Epidemiology</i> , 2014, 38, 670-678.	0.8	174
78	Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. <i>Annals of Oncology</i> , 2014, 25, 2251-2260.	0.6	77
79	Cancer survival in Europe 1999-2007 by country and age: results of EUROCORE-5-a population-based study. <i>Lancet Oncology</i> , The, 2014, 15, 23-34.	5.1	1,554
80	Childhood cancer survival in Europe 1999-2007: results of EUROCORE-5-a population-based study. <i>Lancet Oncology</i> , The, 2014, 15, 35-47.	5.1	799
81	Occupational exposures and colorectal cancers: A quantitative overview of epidemiological evidence. <i>World Journal of Gastroenterology</i> , 2014, 20, 12431.	1.4	36
82	Cancer rehabilitation services: an Italian population-based cohort study. <i>Tumori</i> , 2014, 100, 346-51.	0.6	0
83	Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. <i>International Journal of Cancer</i> , 2013, 132, 2404-2412.	2.3	69
84	Socio-economic inequalities: A review of methodological issues and the relationships with cancer survival. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 266-277.	2.0	123
85	Methodological aspects of estimating rare cancer prevalence in Europe: The experience of the RARECARE project. <i>Cancer Epidemiology</i> , 2013, 37, 850-856.	0.8	21
86	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. <i>European Journal of Cancer</i> , 2013, 49, 2565-2578.	1.3	91
87	Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. <i>European Journal of Cancer</i> , 2013, 49, 684-695.	1.3	519
88	Cancer prevalence estimates in Europe at the beginning of 2000. <i>Annals of Oncology</i> , 2013, 24, 1660-1666.	0.6	36
89	Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. <i>BMJ Open</i> , 2013, 3, e003055.	0.8	72
90	Variations in Cancer Survival and Patterns of Care Across Europe: Roles of Wealth and Health-Care Organization. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 79-87.	0.9	38

#	ARTICLE	IF	CITATIONS
91	Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course. Journal of the National Cancer Institute Monographs, 2013, 2013, 124-130.	0.9	28
92	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	1.7	35
93	Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta OncolÃ³gica, 2012, 51, 441-453.	0.8	88
94	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. European Journal of Cancer, 2012, 48, 159-169.	1.3	37
95	Rare cancers of the head and neck area in Europe. European Journal of Cancer, 2012, 48, 783-796.	1.3	55
96	Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. European Journal of Cancer, 2012, 48, 1167-1175.	1.3	71
97	Incidence and survival of rare urogenital cancers in Europe. European Journal of Cancer, 2012, 48, 456-464.	1.3	132
98	Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995â€“2002. European Journal of Cancer, 2012, 48, 1417-1424.	1.3	42
99	Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 2012, 48, 1532-1542.	1.3	248
100	Embryonal cancers in Europe. European Journal of Cancer, 2012, 48, 1425-1433.	1.3	39
101	Invasive extramammary Pagetâ€™s disease and the risk for secondary tumours in Europe. European Journal of Surgical Oncology, 2012, 38, 214-221.	0.5	63
102	Oesophageal cancer survival in Europe: A EURO CARE-4 study. Cancer Epidemiology, 2012, 36, 505-512.	0.8	108
103	Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 2012, 48, 3257-3266.	1.3	158
104	Survival of European patients with central nervous system tumors. International Journal of Cancer, 2012, 131, 173-185.	2.3	64
105	The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori, 2012, 98, 550-8.	0.6	6
106	Rare cancers are not so rare: The rare cancer burden in Europe. European Journal of Cancer, 2011, 47, 2493-2511.	1.3	573
107	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2011, 79, 65-83.	2.0	58
108	Prognoses for head and neck cancers in Europe diagnosed in 1995â€“1999: a population-based study. Annals of Oncology, 2011, 22, 165-174.	0.6	35

#	ARTICLE	IF	CITATIONS
109	European disparities in malignant digestive endocrine tumours survival. <i>International Journal of Cancer</i> , 2010, 126, 2928-2934.	2.3	57
110	Major and minor salivary gland tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 134-148.	2.0	387
111	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 106-133.	2.0	285
112	Patterns of care for European colorectal cancer patients diagnosed 1996â€“1998: A EUROCARE High Resolution Study. <i>Acta OncolÃ³gica</i> , 2010, 49, 776-783.	0.8	58
113	The Burden of Rare Cancers in Europe. <i>Advances in Experimental Medicine and Biology</i> , 2010, 686, 285-303.	0.8	52
114	Survival for ethmoid sinus adenocarcinoma in European populations. <i>Acta OncolÃ³gica</i> , 2009, 48, 992-998.	0.8	22
115	Prostate cancer treatment in Europe at the end of 1990s. <i>Acta OncolÃ³gica</i> , 2009, 48, 867-873.	0.8	11
116	Survival from salivary glands adenoid cystic carcinoma in European populations. <i>Oral Oncology</i> , 2009, 45, 669-674.	0.8	94
117	Cholangiocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 259-270.	2.0	144
118	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 160-182.	2.0	14
119	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 165-179.	2.0	56
120	The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. <i>European Journal of Cancer</i> , 2009, 45, 909-930.	1.3	120
121	Long-term survival expectations of cancer patients in Europe in 2000â€“2002. <i>European Journal of Cancer</i> , 2009, 45, 1028-1041.	1.3	87
122	The advantage of women in cancer survival: An analysis of EUROCARE-4 data. <i>European Journal of Cancer</i> , 2009, 45, 1017-1027.	1.3	233
123	EUROCARE-4. Survival of cancer patients diagnosed in 1995â€“1999. Results and commentary. <i>European Journal of Cancer</i> , 2009, 45, 931-991.	1.3	740
124	The cancer survival gap between elderly and middle-aged patients in Europe is widening. <i>European Journal of Cancer</i> , 2009, 45, 1006-1016.	1.3	186
125	Survival trends in European cancer patients diagnosed from 1988 to 1999. <i>European Journal of Cancer</i> , 2009, 45, 1042-1066.	1.3	133
126	Multiple tumours in survival estimates. <i>European Journal of Cancer</i> , 2009, 45, 1080-1094.	1.3	109

#	ARTICLE	IF	CITATIONS
127	The cure of cancer: A European perspective. <i>European Journal of Cancer</i> , 2009, 45, 1067-1079.	1.3	80
128	Survival of European children and young adults with cancer diagnosed 1995â€“2002. <i>European Journal of Cancer</i> , 2009, 45, 992-1005.	1.3	442
129	Comparative cancer survival information in Europe. <i>European Journal of Cancer</i> , 2009, 45, 901-908.	1.3	123
130	Oligodendroglioma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 262-272.	2.0	64
131	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 139-152.	2.0	156
132	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. <i>European Journal of Cancer</i> , 2008, 44, 579-587.	1.3	32
133	Cancer survival in five continents: a worldwide population-based study (CONCORD). <i>Lancet Oncology</i> , The, 2008, 9, 730-756.	5.1	1,059
134	Human Papillomavirus in HNSCC: A European Epidemiologic Perspective. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1143-1153.	0.9	40
135	Survival in Patients With Uveal Melanoma in Europe. <i>JAMA Ophthalmology</i> , 2008, 126, 1413.	2.6	95
136	Incidence of Uveal Melanoma in Europe. <i>Ophthalmology</i> , 2007, 114, 2309-2315.e2.	2.5	327
137	Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century. <i>American Journal of Gastroenterology</i> , 2007, 102, 1661-1670.	0.2	121
138	Recent cancer survival in Europe: a 2000â€“02 period analysis of EURO CARE-4 data. <i>Lancet Oncology</i> , The, 2007, 8, 784-796.	5.1	819
139	Anaplastic astrocytoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 72-80.	2.0	67
140	Ependymoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 81-89.	2.0	147
141	Trends in cervical cancer survival in Europe, 1983â€“1994: A population-based study. <i>Gynecologic Oncology</i> , 2007, 105, 609-619.	0.6	29
142	Late outcomes of colorectal cancer treatment: a FECS-EURO CARE study. <i>Journal of Cancer Survivorship</i> , 2007, 1, 247-254.	1.5	12
143	Renal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 247-262.	2.0	33
144	Survival from rare cancer in adults: a population-based study. <i>Lancet Oncology</i> , The, 2006, 7, 132-140.	5.1	120

#	ARTICLE	IF	CITATIONS
145	Incidence of and survival from Wilms's tumour in adults in Europe: Data from the EURO CARE study. <i>European Journal of Cancer</i> , 2006, 42, 2363-2368.	1.3	56
146	Ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 159-179.	2.0	186
147	Hodgkin disease survival in Europe and the U.S.. <i>Cancer</i> , 2006, 107, 352-360.	2.0	64
148	Cancer Survival in Europe and the United States. , 2006, , 112-122.		1
149	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 209-241.	2.0	73
150	Germ cell tumours of the testis. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 141-164.	2.0	77
151	Cancer of the penis. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 165-177.	2.0	82
152	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 379-396.	2.0	89
153	Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. <i>Gut</i> , 2005, 54, 268-273.	6.1	114
154	Childhood Cancer Survival Trends in Europe: A EURO CARE Working Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 3742-3751.	0.8	276
155	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. <i>Annals of Oncology</i> , 2004, 15, 1136-1142.	0.6	22
156	Adult acute myeloid leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 197-222.	2.0	144
157	Adult acute lymphoblastic leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 223-261.	2.0	79
158	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 145-170.	2.0	29
159	Cancer of pancreas. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 147-155.	2.0	19
160	Breast carcinoma survival in Europe and the United States. <i>Cancer</i> , 2004, 100, 715-722.	2.0	163
161	Explaining gastric cancer survival differences among European countries. <i>International Journal of Cancer</i> , 2004, 109, 737-741.	2.3	75
162	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 121-143.	2.0	8

#	ARTICLE	IF	CITATIONS
163	Lower incidence rates but thicker melanomas in Eastern Europe before 1992. <i>European Journal of Cancer</i> , 2004, 40, 1045-1052.	1.3	32
164	Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. <i>International Journal of Cancer</i> , 2003, 106, 416-422.	2.3	241
165	Cancer of the nasopharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 199-214.	2.0	50
166	Cancer of the larynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 65-80.	2.0	98
167	Cancer survival in European adolescents and young adults. <i>European Journal of Cancer</i> , 2003, 39, 2600-2610.	1.3	84
168	Comparison of stomach cancer incidence and survival in four continents. <i>European Journal of Cancer</i> , 2003, 39, 1603-1609.	1.3	102
169	Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. <i>European Journal of Cancer</i> , 2003, 39, 2214-2222.	1.3	107
170	EUROCARE-3: survival of cancer patients diagnosed 1990-1994 results and commentary. <i>Annals of Oncology</i> , 2003, 14, v61-v118.	0.6	638
171	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. <i>Annals of Oncology</i> , 2003, 14, v128-v149.	0.6	400
172	Cancer prevalence in Northern Europe: the EUROPREVAL study. <i>Annals of Oncology</i> , 2003, 14, 946-957.	0.6	18
173	Electronic availability of EUROCARE-3 data: a tool for further analysis. <i>Annals of Oncology</i> , 2003, 14, v150-v155.	0.6	28
174	Cancer prevalence in Central Europe: the EUROPREVAL Study. <i>Annals of Oncology</i> , 2003, 14, 313-322.	0.6	54
175	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. <i>Annals of Oncology</i> , 2003, 14, v14-v27.	0.6	74
176	Childhood cancer survival in Europe. <i>Annals of Oncology</i> , 2003, 14, v119-v127.	0.6	119
177	Cancer prevalence in European registry areas. <i>Annals of Oncology</i> , 2002, 13, 840-865.	0.6	164
178	Measuring cancer prevalence in Europe: the EUROPREVAL Project. <i>Annals of Oncology</i> , 2002, 13, 831-839.	0.6	88
179	A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. <i>Annals of Oncology</i> , 2002, 13, 1128-1139.	0.6	30
180	Childhood cancer survival in Europe and the United States. <i>Cancer</i> , 2002, 95, 1767-1772.	2.0	231

#	ARTICLE	IF	CITATIONS
181	Survival of childhood lymphomas in Europe, 1978â€“1992. European Journal of Cancer, 2001, 37, 703-710.	1.3	31
182	Survival of children with bone sarcoma in Europe since 1978. European Journal of Cancer, 2001, 37, 760-766.	1.3	99
183	Childhood cancer survival in Europe, 1978â€“1992. European Journal of Cancer, 2001, 37, 671-672.	1.3	42
184	Childhood melanoma in Europe since 1978. European Journal of Cancer, 2001, 37, 780-784.	1.3	62
185	Survival of children with soft-tissue sarcoma in Europe since 1978. European Journal of Cancer, 2001, 37, 767-774.	1.3	56
186	The EUROCARE study of survival of cancer patients in Europe. European Journal of Cancer, 2001, 37, 673-677.	1.3	33
187	Survival of children with liver tumours in Europe 1978â€“1989. European Journal of Cancer, 2001, 37, 744-749.	1.3	4
188	Survival of children with thyroid cancer in Europe 1978â€“1989. European Journal of Cancer, 2001, 37, 775-779.	1.3	13
189	Survival for retinoblastoma in Europe. European Journal of Cancer, 2001, 37, 730-735.	1.3	30
190	Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978â€“1992. European Journal of Cancer, 2001, 37, 687-694.	1.3	33
191	Childhood malignancies in the EUROCARE study. European Journal of Cancer, 2001, 37, 678-686.	1.3	33
192	Childhood cancer survival in Europe. European Journal of Cancer, 2001, 37, 810-816.	1.3	43
193	Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978. European Journal of Cancer, 2001, 37, 695-702.	1.3	16
194	Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992. European Journal of Cancer, 2001, 37, 711-721.	1.3	47
195	Survival of children with Wilms' tumour in Europe. European Journal of Cancer, 2001, 37, 736-743.	1.3	14
196	Veno-occlusive disease with multi-organ involvement following actinomycin-D. European Journal of Cancer, 2001, 37, 1141-1148.	1.3	34
197	Cancer survival increases in Europe, but international differences remain wide. European Journal of Cancer, 2001, 37, 1659-1667.	1.3	135
198	Cancer survival differences between European populations: the UK uneasiness. British Journal of Cancer, 2001, 85, 785-786.	2.9	3

#	ARTICLE	IF	CITATIONS
199	Survival for colorectal cancer Reply. Gut, 2001, 48, 868-869.	6.1	1
200	Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut, 2000, 47, 533-538.	6.1	234
201	Variation in survival of patients with lung cancer in Europe, 1985-1989. European Journal of Cancer, 1998, 34, 2191-2196.	1.3	135
202	Improved survival for patients with testicular cancer in Europe since 1978. European Journal of Cancer, 1998, 34, 2236-2240.	1.3	34
203	Improving survival of melanoma patients in Europe since 1978. European Journal of Cancer, 1998, 34, 2197-2203.	1.3	20
204	Variation in survival for adults with Nasopharyngeal cancer in Europe, 1978-1989. European Journal of Cancer, 1998, 34, 2162-2166.	1.3	27
205	Variations in survival from breast cancer in Europe by age and country, 1978-1989. European Journal of Cancer, 1998, 34, 2204-2211.	1.3	52
206	The prognostic role of gender in survival of adult cancer patients. European Journal of Cancer, 1998, 34, 2271-2278.	1.3	135
207	Survival of European women with gynaecological tumours, during the period 1978-1989. European Journal of Cancer, 1998, 34, 2218-2225.	1.3	76
208	Survival of colorectal cancer patients in Europe during the period 1978-1989. European Journal of Cancer, 1998, 34, 2176-2183.	1.3	133
209	Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. European Journal of Cancer, 1998, 34, 2154-2161.	1.3	96
210	Survival of patients with oesophageal and gastric cancers in Europe. European Journal of Cancer, 1998, 34, 2167-2175.	1.3	110
211	Improvement in survival of patients with cancer of the kidney in Europe. European Journal of Cancer, 1998, 34, 2232-2235.	1.3	9
212	The EUROCARE II study. European Journal of Cancer, 1998, 34, 2139-2153.	1.3	61
213	Survival of adult patients with cancer of soft tissues or bone in Europe. European Journal of Cancer, 1998, 34, 2212-2217.	1.3	37
214	Survival rates for primary malignant brain tumours in Europe. European Journal of Cancer, 1998, 34, 2241-2247.	1.3	33
215	Variation in survival of adult patients with thyroid cancer in Europe. European Journal of Cancer, 1998, 34, 2248-2252.	1.3	42
216	Variation in survival of adult patients with haematological malignancies in Europe since 1978. European Journal of Cancer, 1998, 34, 2253-2263.	1.3	40

#	ARTICLE	IF	CITATIONS
217	Estimation and projections of colorectal cancer trends in Italy. <i>International Journal of Epidemiology</i> , 1997, 26, 924-932.	0.9	29
218	Substantial variation in therapy for colorectal cancer across Europe: EURO CARE analysis of cancer registry data for 1987. <i>European Journal of Cancer</i> , 1996, 32, 831-835.	1.3	41
219	Comparisons of colon cancer survival among european countries: The eurocare study. <i>International Journal of Cancer</i> , 1995, 63, 43-48.	2.3	64
220	Estimation and projections of stomach cancer trends in Italy. <i>Cancer Causes and Control</i> , 1995, 6, 339-346.	0.8	23
221	Time trends of lung and larynx cancers in Italy. <i>International Journal of Cancer</i> , 1994, 57, 154-161.	2.3	32
222	Survival for lung cancer in northern Italy. <i>Cancer Causes and Control</i> , 1992, 3, 223-230.	0.8	15
223	Survival and age at diagnosis of breast cancer in a population-based cancer registry. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 981-984.	0.9	55
224	Breast cancer incidence and prevalence estimated from survival and mortality. <i>Cancer Causes and Control</i> , 1990, 1, 23-29.	0.8	45
225	Letter to the editor. <i>International Journal of Cancer</i> , 1989, 44, 186-187.	2.3	6